Accessibility Menu
Vg Life Sciences logo

Vg Life Sciences(OTC) VGLS

Current Price$0.36
Market Cap$506.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)-100%
5 Year-100%
1 Year-76%
1 Month-8%
Vg Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.482026-07-24
Vg Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1,085.19%USD 0.042026-07-17
1 month-7.69%USD 0.522026-06-24
3 month+11.84%USD 0.432026-04-24
Year to date-76%USD 2.002025-12-30
1 year-76%USD 2.002025-07-23
3 year-76%USD 2.002023-07-25
5 year-99.62%USD 126.002021-07-23
Since inception-100%USD 17,767,106.842001-10-03

Vg Life Sciences Financials at a Glance

Market Cap

$506.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$355.18K

EPS (TTM)

-$0.20

P/E Ratio

-2.40

Dividend

$0.00

Beta (Volatility)

46.88 (High)

Price

$0.36

Volume

284

Open

$0.36

Previous Close

$0.48

Daily Range

$0.36 - $0.36

52-Week Range

$0.02 - $2.25

Estimated Earnings Date

Nov 5, 2025

VGLS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vg Life Sciences

SB Technology Holdings Inc. is a financial services company based in New York, primarily operating as a subsidiary of KH Feelux Co., Ltd. The company has historically engaged in the research and development of pharmaceutical and medical products, although it currently does not have significant operations.

Products and Services
  • Research and development of therapeutic and diagnostic products
  • Consulting services in the pharmaceutical sector
  • Investment opportunities in emerging technologies
Growth Outlook
  • Recent quarterly net income showed a significant increase to $199,728
  • Trailing twelve months (TTM) net income improved compared to previous periods
  • Potential for future growth through strategic partnerships and investments
Financial Highlights
  • Quarterly revenue remains at $0, indicating a focus on cost management
  • Net income for Q4 2025 was $199,728, a notable recovery
  • Current liabilities totaled approximately $4.56 million, reflecting financial stability
SB Technology Holdings Inc. operates in a niche market with a focus on pharmaceutical research and development. Despite not having significant operations currently, the company has shown resilience in its financial performance, particularly with a positive net income reported in the most recent quarter. The absence of revenue highlights a strategic pivot towards managing costs while exploring potential growth avenues. The company's financial position, characterized by manageable liabilities, suggests a foundation for future opportunities. Investors may find interest in the company's potential to leverage its historical expertise in the pharmaceutical sector and explore new avenues for growth.
AI Generated • Jul 23, 2026

Industry

Biotechnology

Sector

Health Care

CEO

William P. Farrand

Website

vglscorp.com

Headquarters

New York, NY 10013, US

VGLS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

0.00%

Earnings Yield

-41.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$506.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.05M

Volume

284

Avg. Volume

8.62K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$296.55K

EBITDA

-$541.09K

Operating Cash Flow

-$22.46K

Capital Expenditure

$0.00

Free Cash Flow

-$22.46K

Cash & ST Invst.

$0.00

Total Debt

$2.11M

Vg Life Sciences Performance Analysis

Vg Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Vg Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Vg Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 3.80N/A
20232023-12-31USD -3.00N/A
20242024-12-31USD -0.20-93.3%
20252025-12-31USD -0.40100.0%
Vg Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31103.2%
Q22025-06-30-361.8%
Q32025-09-30N/A
Q42025-12-31200.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$506.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$506.30K

N/A

Employees

1

N/A

Net Income

$199.73K

+176.3%

EBITDA

-$78.60K

+70.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$0.00

N/A

Total Debt

$2.11M

+3.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$2.11M

+3.4%

Return on Assets

0.00%

N/A

Return on Invested Capital

0.00%

N/A

Free Cash Flow

-$6.19K

-52.0%

Operating Cash Flow

-$6.19K

-52.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AGTXAgentix Corp.
$0.02+0.00%
RGBPRegen BioPharma, Inc.
$0.00-33.33%
AGNPFGrey Matters Health Inc.
$0.30+2.24%
APLIFAppili Therapeutics Inc
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.28+0.11%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.22-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$45.95+0.03%
BMNRBitmine Immersion Technologies
$17.65+0.12%

Questions About VGLS

What is the current price of Vg Life Sciences?

Vg Life Sciences is trading at $0.36 per share.

What is the 52-week range for Vg Life Sciences?

Over the past 52 weeks, Vg Life Sciences has traded between $0.02 and $2.25.

How much debt does Vg Life Sciences have?

As of the most recent reporting period, Vg Life Sciences reported total debt of $486.15K.

How much cash does Vg Life Sciences have on hand?

Vg Life Sciences reported $0.00 in cash and cash equivalents in its most recent financial results.

What is Vg Life Sciences’s dividend yield?

Vg Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services